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 Abstract 
 Full-gene sequencing undoubtedly comes with its pluses and its minuses. In this article, the 
authors aim to weigh up the pros and cons not only from the point of view of the patient but 
also in view of the doctor’s possible perspective. Either party may be for or against it for a 
variety of reasons – for example, a fear of knowing too much on the part of the patient, and 
concerns about possible over-treatment on the part of the healthcare professional. One thing 
is certain: the possibility of full-gene sequencing is here and here to stay. At the very least, 
doctors need to make patients aware of their options, while offering balanced advice. 
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 Learning to Communicate 
 Communication is key in the modern world of medicine. Patients and healthcare workers 
are having more and more discussions to determine, by co-decision, the best treatment path 
for the individual  [1] .
 There are, of course, problems with this in that many healthcare professionals (HCPs) are 
not up to speed with the more recent developments in, say, personalised medicine and its 
reliance on genetics, imaging and other complex factors  [2] .
 Things are moving so quickly in so many fields, and it is difficult for an HCP to know abso-
lutely everything, but we must try to improve this situation.
 Also, while the internet has undoubtedly opened more doors to patient awareness, the 
downside is that so much information out there can be misleading and, therefore, so-called 
self-diagnosis can lead to unnecessary stress on the part of the patient.
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 As argued elsewhere in this special issue, health literacy is extremely important on both 
sides of the treatment “fence.” Ongoing education and training for HCPs is a vital component 
as we move forward with more individualised medicine  [3] .
 A further problem, however, is that even the most savvy and up-to-date doctor, nurse or 
other HCP may not have the best chance to communicate in an optimal way, covering all the 
bases, given the workload and time constraints (10-min average consultation times in the UK 
and elsewhere, for example)  [4] .
 Many doctors have the famous “good bedside manner,” yet even the smartest of patients 
will sometimes fail to ask the right, direct questions. When he or she doesn’t, the HCP may not 
have the chance to fill in the gaps due to the ticking of the clock.
 There is also the matter of patients being a little frightened to ask for a second opinion 
(to which they are entitled), pushing a question if they don’t understand the answer fully, 
asking about clinical trials and discussing their own medical data.
 Even with the best will in the world from the doctor, it can be intimidating. Especially as 
the patient also has to contend with worrying about his or her condition in the first place.
 There is nothing really new in that, and it should have moved forward by now, yet hasn’t.
 The Pros and Cons of Gene Sequencing 
 What is new, however, is the possibility of a patient undergoing full-gene sequencing. The 
price has come down significantly, although HCPs may be reluctant to recommend it for 
several reasons, and patients may also be reluctant  [5] .
 Below are two hypothetical conversations. The first is between an HCP and an 18-year-old 
man (let’s call him “John”) who has been doing some reading on genetics.
 John: Doctor, I’m interested in having my genes sequenced. My grandfather and one uncle 
both died young of heart attacks, although my father has a healthy heart. I want to know the 
risks. Also, two other relatives died from lung cancer in their mid-60s…
 HCP: Do you smoke?
 John: No.
 HCP: Well, that one’s easy. Don’t start. You don’t need gene sequencing for that.
 John: Um, ok. What about the heart attack issue?
 HCP: Many things contribute to the risk of heart disease: lack of exercise, obesity and the 
wrong foods, too much drinking, the aforementioned smoking… Just live a healthy lifestyle 
and you’ll probably be fine and have a good, long life.
 John: But my uncle did everything in moderation and still had a heart attack. He didn’t 
even smoke! I just want to know what the risks are – whether there’s something in my 
make-up that means that, whatever I do in the right way, I’m still high risk.
 HCP: You’d really want to know 30 years in advance that there’s a large chance of you 
having a heart attack? Wouldn’t that give you too much stress, and stop you enjoying life? I’d 
have a heart attack myself, just thinking about it at your age.
 And what if we found something else along the way? A propensity for a certain other 
cancer? None of us live forever – we’ll all die of something. Why stress yourself out at such a 
young age?
 John: But…
 HCP: And what if you have kids? Then you’ll spend your life as a father worrying about 
what you may have passed down to them. That’s if you told your wife in the first place. And 
how would she feel?
 Then, if you decided to have kids anyway, would you tell the children? Would they want 
you to? Just because you have the option of gene sequencing, doesn’t mean you have to take 
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it. All the hundreds of generations before you managed well enough without that kind of fore-
knowledge.
 John: But I want to do it. Just because I can, I guess.
 HCP: Well, I can’t stop you, but you won’t be doing it through me, as I strongly advise 
against it. You’re too young to need to know all this.
 John: Ok, but…
 And so on…
 The next scenario involves an older man (Ted) in his late 40s. This time we have an HCP 
with a different view for different reasons.
 HCP: Ted, I’ve been thinking, there are very good reasons why you should have your 
genes sequenced.
 Ted: Eh? What’s that, then?
 HCP: In simple terms it means we can test your DNA and look for any problems that are 
likely to arise in the future, like a cancer that’s lying dormant, prostate trouble, that sort of 
thing. In this way we can take preventative measures.
 Ted: But I’m only 47, why would I want to do that? I’m as fit as a fiddle. Well, mostly. But 
I don’t want to know that I’m going to die of leprosy or something at 82. I’d be counting down 
the minutes!
 HCP: I understand that, but you’re almost at an age when things can start to go wrong. I 
don’t want to alarm you, as there is no current evidence regarding yourself, but we all have 
different genes and, these days, we can use them to target therapy to you personally, even 
before a disease flares up.
 Modern methods mean, firstly, we can figure out the likelihood of you developing a 
certain disease and take early measures to manage it. Secondly, it will give us clues to the best 
treatment – for example, chemotherapy is a waste of time and resources in some cancer 
patients – and, thirdly, with your consent we could share your information, anonymously, to 
help other people down the line.
 Ted: But I’m 47! Why not ask me in ten years?
 HCP: Because now is a perfect time. Let’s nip any potential problems in the bud. You’ll be 
helping yourself and society and, if any urgent problems do appear, we’ll be able to deal with 
it at the earliest stage possible.
 Ted: Um. I  do like the thought of sharing the information to help others. But I’ll have to 
talk it over with my wife. It will have an impact on her too, you know?
 HCP: Of course it will. And if you want to talk to me about it together, then that’s no 
problem at all.
 In a third scenario, a young couple could have issues involving their fears about passing 
on a congenital condition (that they don’t know about) to their, as yet, unborn children, but 
may also want to know what the risks are.
 Six Pillars for Policy Makers 
 It’s a fine balance. And, while it’s clear that gene sequencing has huge advantages for 
research and prevention, there can be pitfalls for individuals and their families. In this day 
and age HCPs need to look at both sides of the coin, as the new science is certainly not going 
away.
 Let’s finish by floating the idea that the concept of having full-gene sequencing, and 
understanding the consequences, should be raised in older school children (in a similar way 
to sex education) as well as at universities, within HCP training courses (mandatory), and 
with other stakeholders such as patient groups and even mainstream journalists. For the 
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broader policy and regulatory communities, the following six pillars need to be taken into 
account:
 1. Standards for data generation and analysis –  Agree on standards for genomic sequencing 
and analysis : Genome sequencing has progressed rapidly in clinical and translational 
research with the development of multiple tools and methods. Defining standards will 
ensure consistency of clinical testing and also greatly further research by facilitating 
greater comparability of the increasing number of sequences being performed. 
 2. Data privacy and sharing –  Agree on standards around the sharing of genomic and 
associated clinical data : Genome sequences are by definition personal and have the 
potential to be identifiable; however, the sharing of data greatly increases the utility of 
genome sequencing, for example, in confirming the pathogenicity of an identified 
genetic change and identifying other patients with the same rare disease. 
 3. Clinical informatics –  Promote the uptake and alignment of existing agreed-on standards 
and define standards for the interoperability of health informatics systems : Electronic 
patient record systems are variably implemented across Europe, but they have few 
uniform standards and little interoperability. The linking of clinical to genomic data is 
essential to derive benefit from genomic data, for both health and research purposes. 
 4. Clinical application –  Coordinate national activity to ensure best practice emerging with 
regard to clinical implementation and application is shared : Genomics is starting to be 
implemented across a number of clinical areas in different geographies. To ensure that 
models of best practice for clinical implementation and application are shared across 
these, a coordinating body is required. 
 5. Clinical education –  Structure a training programme in genomics, informatics and 
personalised medicine for clinical staff : The majority of current clinicians have not been 
trained in the “genomic era” and have little experience with using genetic information 
in healthcare. For patients to be correctly identified for the most relevant test, and the 
appropriate information from the results to be conveyed back to them, the general 
workforce needs specific addressing of this educational deficit. 
 6. Regulation –  Promote broad discussion with European regulators on the appropriate 
regulatory mechanism for clinical genomic testing : Current regulatory mechanisms can 
make the prompt implementation of effective innovative diagnostics to patients 
challenging, particularly as genomic tests tend to rapidly evolve and improve after 
initial release in terms of undergoing frequent hardware, reagent and analysis/
interpretation software modifications  [2] . 
 Perhaps it’s an idea that will catch on, as the gene genie is well and truly out of the bottle.
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